Literature DB >> 30352668

Effectiveness of Integrated Dual Diagnosis Treatment (IDDT) in severe mental illness outpatients with a co-occurring substance use disorder.

Martijn Kikkert1, Anneke Goudriaan2, Marleen de Waal2, Jaap Peen3, Jack Dekker4.   

Abstract

Integrating substance use disorder treatment with psychiatric treatment is considered more favourable then treating these disorders parallel or sequential, but the evidence base is inconclusive. We examined the effectiveness of Integrated Dual Diagnosis Treatment (IDDT) on substance use in severe mental illness outpatients with substance use disorders. IDDT is a collaborative, multidisciplinary team approach in which motivational interviewing is a key element. In addition, we also examined the effects of IDDT implementation on skills and knowledge of mental health care professionals. A randomized controlled stepped-wedge cluster trial was performed in 6 functional assertive cummunity treatment teams. We included 37 clinicians who were given a three-day IDDT training. Our primary outcome was days of substance use at follow up, 12 months after IDDT implementation. This was assessed in 154 included patients and was measured with the Measurement in the Addiction for Triage and Evaluation. After implementation of IDDT we found a reduction in the number of days patients used alcohol or drugs, but no improvements on other secondary outcomes such as psychopathology, functioning, therapeutic alliance or motivation to change. Also, IDDT training did not seem to improve clinicians' knowledge, attitudes and motivational interviewing skills. Effects on our secondary outcomes may have been limited by the absence of a training effect in our clinicians. Our study clearly underlines the complexity of disseminating IDDT and in particular motivational interviewing.
Copyright © 2018 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Dual diagnosis; Implementation; Integrated treatment; Motivational interviewing; Substance use disorder

Mesh:

Year:  2018        PMID: 30352668     DOI: 10.1016/j.jsat.2018.09.005

Source DB:  PubMed          Journal:  J Subst Abuse Treat        ISSN: 0740-5472


  7 in total

1.  Behavioral Crisis and First Response: Qualitative Interviews with Chicago Stakeholders.

Authors:  Conor H Murray; Juan L Contreras; Caroline H Kelly; Deborah K Padgett; Harold A Pollack
Journal:  Community Ment Health J       Date:  2022-06-25

2.  Dropout Rates in Psychosocial Interventions for People With Both Severe Mental Illness and Substance Misuse: A Systematic Review and Meta-Analysis.

Authors:  Marianne Bouchard; Tania Lecomte; Briana Cloutier; Jessica Herrera-Roberge; Stéphane Potvin
Journal:  Front Psychiatry       Date:  2022-05-12       Impact factor: 5.435

3.  The relationship of Medicaid expansion to psychiatric comorbidity care within substance use disorder treatment programs.

Authors:  Chelsea L Shover; Amanda Abraham; Thomas D'Aunno; Peter D Friedmann; Keith Humphreys
Journal:  J Subst Abuse Treat       Date:  2019-07-29

4.  Association of co-occurring opioid or other substance use disorders with increased healthcare utilization in patients with depression.

Authors:  Veer Vekaria; Budhaditya Bose; Sean M Murphy; Jonathan Avery; George Alexopoulos; Jyotishman Pathak
Journal:  Transl Psychiatry       Date:  2021-05-03       Impact factor: 6.222

5.  Effects of a web-based relapse prevention program on abstinence: Secondary subgroup analysis of a pilot randomized controlled trial.

Authors:  Ayumi Takano; Yuki Miyamoto; Tomohiro Shinozaki; Toshihiko Matsumoto; Norito Kawakami
Journal:  Neuropsychopharmacol Rep       Date:  2022-06-11

6.  Ensuring access to high-quality substance use disorder treatment for Medicaid enrollees: A qualitative study of diverse stakeholders' perspectives.

Authors:  Jenny Zhen-Duan; Marie Fukuda; Melissa DeJonckheere; Irene Falgas-Bagué; Steven Miyawaki; Parwana Khazi; Margarita Alegría
Journal:  J Subst Abuse Treat       Date:  2021-05-31

7.  Addressing Dual Disorders in a Medium-Term Admission Unit.

Authors:  Francisco Arnau; Ana Benito; Mariano Villar; María Elena Ortega; Lucía López-Peláez; Gonzalo Haro
Journal:  Brain Sci       Date:  2021-12-26
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.